- Home
- SOPH vs PROK Comparison
SOPH vs PROK Comparison
Compare SOPH & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOPH | PROK |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 367.7M | 331.2M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SOPH | PROK |
|---|---|---|
| Price | $4.66 | $1.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $7.00 | ★ $7.40 |
| AVG Volume (30 Days) | 104.4K | ★ 704.0K |
| Earning Date | 03-03-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | $23.09 | N/A |
| Revenue Next Year | $19.57 | $25.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $2.58 | $0.46 |
| 52 Week High | $5.70 | $7.13 |
Technical Indicators
Market Signals| Indicator | SOPH | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 44.60 | 27.38 |
| Support Level | $4.54 | $0.54 |
| Resistance Level | $4.86 | $2.58 |
| Average True Range (ATR) | 0.27 | 0.14 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 24.26 | 0.00 |
Price Performance
Historical ComparisonAbout SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.